全脑放疗联合替莫唑胺化疗治疗脑转移肿瘤的疗效及安全性分析

Analysis Efficacy and Safety of Whole Brain Radiotherapy Combined with Temozolomide Chemotherapy in Treatment of Brain Metastases

目的探讨并分析给予脑转移肿瘤患者全脑放疗联合替莫唑胺化疗治疗的疗效及安全性。方法方便选取2013年5月—2016年4月在该院就诊的脑转移肿瘤患者110例,将其随机分为两组,各55例。对照组患者给予全脑放射治疗,观察组患者给予全脑放疗联合替莫唑胺化疗治疗,对比分析两组患者的不良反应、生存时间、近期疗效等。结果观察组患者近期治疗有效率为96.36%,明显高于对照组的70.90%,差异具有统计学意义(P<0.05);观察组不良反应为47.27%,对照组不良反应为56.36%,两组对比,差异无统计学意义(P>0.05);对照组患者的无进展生存时间(9.12±2.15)个月和中位生存时间(9.42±1.80)个月均低于观察组(12.20±2.75)个月、(13.53±1.46)个月,差异具有统计学意义(P<0.05)。结论给予脑转移肿瘤患者全脑放疗联合替莫唑胺化疗的治疗效果较好,可提高放疗的增敏效果,增强患者脑转移肿瘤的局部控制率,延长患者的生存时间,且安全可靠。

Objective To observe and analyze the efficacy and safety of whole brain radiotherapy （WBRT） combined with temozolomide chemotherapy in treatment of patients with brain metastases. Methods Convenient selected 110 patients with brain metastases treated in the hospital from May 2013 to October 2 0 1 5 were randomly divided into two groups, 55 cases in each . Control group received WBRT and observation group was given WBRT combined with temozolomide chemotherapy. The adverse reactions, survival time, recent efficacy of two groups were compared and analyzed. Results The recent treatment effective rate of observation group was 96.36 % , which was significantly higher than 70 . 90 % of control group （ P 〈0.05）; There was no statistical difference in adverse reactions between observation group （47.27%） and control group （56.36%）（P 〉 0.05）; The progress free survival and median survival time of control group were （9.12±2.15）months and （9.42±1.80）months respectively, which were lower than （12.20±2.75）months and （13.53±1.46）months of observation group （ P 〈0.05）. Conclusion Applying WBRT combined with temozolomide chemotherapy for treating patients with brain metastases has good curative effects, and it can improve the effect of enhanced sensitivity for radiotherapy, enhance the local control ratio of brain metastases for patients and prolong the survival time of p atients, which is safe and reliable.